MQ710 / Imvaq Therap - LARVOL DELTA

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Active, not recruiting ➔ Recruiting

Checkpoint inhibition • Enrollment open • First-in-human • Angiosarcoma • Basal Cell Carcinoma • Head and Neck Cancer • Kaposi Sarcoma • Melanoma • Merkel Cell Carcinoma • Oncology • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • BRAF

Intravesical recombinant MVA therapy induces local and systemic antitumor immunity and memory in an orthotopic murine bladder cancer model (SITC 2025) - "Our first-generation virus, rMVA/MQ710 (MVA∆E5R-Flt3L-OX40L), deletes the viral immune evasion gene E5R and expresses membrane-anchored Flt3L and OX40L to activate innate and adaptive immunity via cGAS/STING and type I IFN signaling...These findings support the clinical development of rMVA-based intravesical immunotherapy for NMIBC.Acknowledgements This work was supported by the Center for Experimental Therapeutics Grant (L.D.), Rockefeller University Center for Clinical and Translational Science (RUCCTS) (L.D, J.A.L, and J.C.O). J.A.L is a Clinical Scholar at the Rockefeller University."

Preclinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • CD8 • IL12A • NOS2 • PTPRC • STING • TNFSF4

Type I IFN receptor signaling in myeloid and T cells drives antitumor immunity elicited by intratumoral delivery of immunogenic recombinant modified vaccinia virus Ankara (AACR 2025) - "Our first-generation virus, MQ710, was developed by deleting E5R, which encodes a cGAS inhibitor, from the non-replicative modified vaccinia virus Ankara (MVA) and incorporating transgenes for membrane-bound Flt3L and OX40L...Single-cell RNA sequencing of CD45+ cells isolated from MB49 tumors from conditional knock-out mice and controls treated with MQ954 twice three days apart further highlighted the pivotal role of type I IFN signaling in monocyte recruitment, macrophage and neutrophil activation and the differentiation of stem-like T cells into effector T cells. This study underscores the multifaceted role of type I IFN signaling across diverse immune cell types in the context of virus-based cancer immunotherapy and provides valuable insights into the intricate immune mechanisms driving antitumor responses."

Bladder Cancer • Brain Cancer • Genito-urinary Cancer • Neurofibrosarcoma • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • CD8 • IFNAR1 • IL12A • IRF7 • PTPRC • STAT2 • TNFSF4

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov) - P1 | N=5 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Recruiting ➔ Active, not recruiting | N=56 ➔ 5

Checkpoint inhibition • Combination therapy • Enrollment change • Enrollment closed • Angiosarcoma • Basal Cell Carcinoma • Head and Neck Cancer • Kaposi Sarcoma • Melanoma • Merkel Cell Carcinoma • Oncology • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • BRAF

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: May 2025 ➔ May 2028 | Trial primary completion date: May 2025 ➔ May 2028

Checkpoint inhibition • Combination therapy • Trial completion date • Trial primary completion date • Angiosarcoma • Basal Cell Carcinoma • Head and Neck Cancer • Kaposi Sarcoma • Melanoma • Merkel Cell Carcinoma • Neuroendocrine Tumor • Non-melanoma Skin Cancer • Oncology • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • BRAF

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center

Checkpoint inhibition • Combination therapy • New P1 trial • Angiosarcoma • Basal Cell Carcinoma • Head and Neck Cancer • Kaposi Sarcoma • Melanoma • Merkel Cell Carcinoma • Neuroendocrine Tumor • Non-melanoma Skin Cancer • Oncology • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • BRAF

Imvaq Therapeutics Raises $15 Million in Series B Financing to Fund IND and Phase 1 Trials (GlobeNewswire) - "Imvaq Therapeutics Corp...announced the closing of its $15 million Series B financing...Imvaq has raised over $25 million in capital to date and these funds will enable the company to catalyze the Phase 1 clinical development of its first therapeutic candidate MQ710, a novel 2^nd-generation viral immunotherapy based on armed Modified Vaccinia Ankara (MVA), and to advance additional novel assets in its pipeline."

Financing • Oncology